Metformin may improve outcomes in patients with non-small cell lung cancer (NSCLC) who are overweight or obese, according to a study published in the Journal of the National Cancer Institute.

The study showed that metformin use was associated with improvements in overall survival (OS) and recurrence-free survival (RFS) for overweight and obese patients who had undergone lobectomy. Researchers also found that metformin was associated with longer progression-free survival (PFS) in overweight NSCLC patients treated with immune checkpoint inhibitors (ICIs).